Association between serum aminotransferase enzymes–lipid profile ratio and spontaneous HCV clearance in blood donors

Papers of special note have been highlighted as: • of interest

References

• 1 Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17 (2), 107–115 (2011).
  Medline CASGoogle Scholar
• 2 Zhang B, Chen K1, Ni E. Comparison of three methods for extraction of HCV RNA in sera collected from individuals with hyperlipidemia, hyperbilirubinemia and hyperglobulinemia. J. Virol. Methods 212, 44–46 (2015).
  Medline CASGoogle Scholar
• 3 Chiang JY. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr. Opin. Investig. Drugs 6(10), 994–1001 (2005).
  Medline CASGoogle Scholar
• 4 Alavian SM, Miri SM, Tabatabaei SV et al. Lipid profiles and hepatitis C viral markers in HCV-infected thalassemic patients. Gut Liver 5(3), 348–355 (2011).
  Medline CASGoogle Scholar
• 5 André P, Komurian-Pradel F, Deforges S et al. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919–6928 (2002). • Suggests that the infectivity of lipoviro particles (LVP) is mediated by endogenous proteins rather than by viral components, providing a mechanism of escape from the humoral immune response.
  Medline CASGoogle Scholar
• 6 Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96(22), 12766–12771 (1999).
  Medline CASGoogle Scholar
• 7 Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 19(2), 95–103 (2011).
  Medline CASGoogle Scholar
• 8 Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90(5), 1055–1070 (2009).
  Medline CASGoogle Scholar
• 9 Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol. Metab. 21(1), 33–40 (2010). • Highlights HCV-altered lipid metabolic events that aid the virus life cycle and ultimately promote liver disease.
  Medline CASGoogle Scholar
• 10 Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat. Med. 19(6), 722–729 (2013). • Results show that HCV uses a novel mechanism to exploit intrinsic innate responses and hijack lipid metabolism, which may contribute to high chronicity rates and the pathological hallmark of steatosis in HCV infection.
  Medline CASGoogle Scholar
• 11 Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral related steatosis. FASEB J. 16(2), 185–194 (2002). • Results lead to propose a new pathophysiological animal model for induction of viral-related steatosis whereby the core protein of HCV targets microsomal triglyceride (TG) transfer protein activity and modify hepatic very low density lipoprotein assembly and secretion.
  Medline CASGoogle Scholar
• 12 Sabile A, Perlemuter G, Bono F et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 30(4), 1064–1076 (1999).
  Medline CASGoogle Scholar
• 13 Petit JM, Jooste V, Duvillard L et al. Apolipoprotein-AII concentrations are associated with liver steatosis in patients with chronic hepatitis C. Dig. Dis. Sci. 52(12), 3431–3434 (2007).
  Medline CASGoogle Scholar
• 14 Felmlee DJ, Sheridan DA, Bridge SH et al. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 139(5), 1774–1783 (2010). • Dietary TG alters the density and dynamics of HCV in plasma. The rapid clearance rate of HCV (VLDF) indicates that association with TRL is important for HCV infectivity. HCV particles, such as exchangeable apolipoproteins, appear to reassociate with TRLs in the vascular compartment.
  Medline CASGoogle Scholar
• 15 Lerat H, Kammoun HL, Hainault I et al. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J. Biol. Chem. 284(48), 33466–33474 (2009). • Transgenic mice expressing the HCV full-length polyprotein at low levels have decreased plasma TG levels and develop hepatocellular steatosis in the same way as HCV-infected patients. In these mice, SREBP1c activation by one or several HCV proteins induces de novo TG synthesis via the lipogenic pathway in a manner independent of endoplasmic reticulum (ER) stress, whereas TG secretion is simultaneously reduced.
  Medline CASGoogle Scholar
• 16 André P, Perlemuter G, Budkowska A, Bréchot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin. Liver Dis. 25(1), 93–104 (2005).
  Medline CASGoogle Scholar
• 17 André P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919–6928 (2002).
  Medline CASGoogle Scholar
• 18 Anand BS1, Velez M. Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World. J. Gastroenterol. 10(16), 2409–2411 (2004).
  MedlineGoogle Scholar
• 19 Barrett S, Goh J, Coughlan B et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 49(3), 423–430 (2001).
  Medline CASGoogle Scholar
• 20 Wietzke-Braun P, Manhardt LB, Rosenberger A et al. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J. Gastroenterol. 13(31), 4224–4229 (2007).
  Medline CASGoogle Scholar
• 21 Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284(4), 450–456 (2000).
  Medline CASGoogle Scholar
• 22 Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346(8981), 1006–1007 (1995).
  Medline CASGoogle Scholar
• 23 Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver Dis. 12(3), 713–726 (2008).
  MedlineGoogle Scholar
• 24 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18(6), 499–502 (1972).
  Medline CASGoogle Scholar
• 25 Guh JY, Lai YH, Yang CY. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 69(4), 459–465 (1995).
  Medline CASGoogle Scholar
• 26 Kaplan MM. Laboratory tests. In: Diseases of the Liver (7th Edition). Sciff LR, Schiff ER (Eds). J.B. Lippincott Company, PA, USA, 108–144 (1993).
  Google Scholar
• 27 Sherlock S (Ed.). Virus hepatitis. In: Diseases of the Liver and Biliary System (6th Edition). Blackwell Scientific Publication, London, UK (1981).
  Google Scholar
• 28 El-Guinidy MA, El-Touny MA, Abdel-Bary MA, Abdel-Fattah SA Metwally A. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am. J. Trop. Med. Hyg. 51(6), 809–818 (1994).
  MedlineGoogle Scholar
• 29 Isselbacher KH, Podolosky DK. Liver and biliary diseases. In: Harrisons Principles of Internal Medicine. Isselbacher KJ, Brauwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (Eds). McGraw-Hill, NY, USA, 438–1448 (1994).
  Google Scholar
• 30 Masoud AM, Hussein MM, Anwar ME et al. Gastric histochemical studies in endemic schistosomal hepatosplenomegaly. J. Egypt. Soc. Parasitol 18(2), 599–507 (1988).
  MedlineGoogle Scholar
• 31 Ravaggi A, Zonara A, Mazza C, Albertini A, Cariai E. Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. J. Clin. Microbiol. 33(2), 265–269 (1995).
  Medline CASGoogle Scholar
• 32 Fabrizi F, Lunghi G, Andrulli S et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol. Dial. Transplant. 12(7), 1394–1398 (1997). • Data show that detectable HCV-RNA in serum is a strong independent predictor of raised aminotransferase values in chronic dialysis patients. The relationship between serum aminotransferase values and anti-HCV antibody was exclusively related to the association between raised aminotransferase values and HCV viremia. HCV-RNA-positive patients show higher hepatic enzyme levels than dialysis patients with no detectable HCV-RNA. No association between HCV genotype and serum aminotransferase activity was apparent.
  Medline CASGoogle Scholar
• 33 Agha S, Al-Gendy M, El-Fiky A, El-Emshaty W. Correlation of serum hepatitis C virus RNA titre with aminotransferases and liver histopathological findings in HCV-seropositive cases with end-stage chronic liver disease. Microbes Infect. 1(13), 1091–1094 (1999).
  Medline CASGoogle Scholar
• 34 Ijaz B1, Ahmad W, Javed FT et al. Association of laboratory parameters with viral factors in patients with hepatitis C. Virol. J. 8, 361 (2011).
  MedlineGoogle Scholar
• 35 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus cholesterol and lipoproteins – impact for the viral life cycle and pathogenesis of liver disease. Viruses 5(5), 1292–1324 (2013).
  MedlineGoogle Scholar
• 36 Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin. Liver Dis. 33(4), 358–368 (2013).
  Medline CASGoogle Scholar
• 37 Murthy GD, Vu K, Venugopal S. Prevalence and treatment of hyper-lipidemia in patients with chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol. 21(8), 902–9007 (2009).
  MedlineGoogle Scholar
• 38 Sheridan DA, Price DA, Schmid ML et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving antiviral agents interferon-alpha and ribavirin. Aliment. Pharmacol. Ther. 29(12), 1282–1290 (2009).
  Medline CASGoogle Scholar
• 39 Negro F. Hepatitis C virus-induced steatosis: an overview. Dig. Dis. 28(1), 294–299 (2010).
  MedlineGoogle Scholar
• 40 Chen L, Liu W, Lai S et al. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur. J. Gastroenterol. Hepatol. 25(8), 935–941 (2013).
  Medline CASGoogle Scholar
• 41 Pereska ZJ, Bozinovska C, Dimitrovski C et al. Plasma apo/lipoproteins disturbances as a precondition for metabolic syndrome in HCV seronegative heroin addicts. Am. J. Drug Alcohol Abuse 37(3), 196–202 (2011).
  MedlineGoogle Scholar
• 42 Ramcharran D, Wahed AS, Conjeevaram HS et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52(3), 854–863 (2010).
  Medline CASGoogle Scholar
• 43 Albecka A, Belouzard S, Op de Beeck A et al. Role of low density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55(4), 998–1007 (2012).
  Medline CASGoogle Scholar
• 44 Corey KE, Mendez-Navarro J, Barlow LL et al. Acute hepatitis C infection lowers serum lipid levels. J. Viral Hepatol. 18(7), 366–371 (2011).
  Google Scholar
• 45 Grunfeld C, Feingold KR. Tumor necrosis factor, interleukin and interferon induced changes in lipid, metabolism as part of host defense. Proc. Soc. Exp. Biol. Med. 200(2), 224–227 (1992).
  Medline CASGoogle Scholar
• 46 Kono Y, Hayashida K, Tanaka H, Ishibashi H, Harada M. High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. J. Med. Virol. 70(1), 42–48 (2003).
  Medline CASGoogle Scholar
• 47 Marzouk D, Sass J, Bakr I et al. Metabolic and cardiovascular risk profiles and hepatitis C. virus infection in rural Egypt. Gut 56(8), 1105–1110 (2007).
  Medline CASGoogle Scholar
• 48 Dai CY, Huang JF, Hsieh MY et al. link between triglyceride levels, hepatitis C virus infection and diabetes. Gut 56(8), 1167–1168 (2007).
  MedlineGoogle Scholar
• 49 Ryder S. Do high lipids help clearance of hepatitis C? Gut 56(8), 1044–1045 (2007).
  MedlineGoogle Scholar
• 50 Li H1, Liu Z, Han Q, Li Y, Chen J. Association of genetic polymorphism of low-density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese. J. Med. Virol. 78(10), 1289–1295 (2006).
  Medline CASGoogle Scholar
• 51 Dunlop JI, Owsianka AM, Cowton VM, Patel AH. Current and future prophylactic vaccines for hepatitis C virus. Vaccine (Auckl.) 5, 31–44 (2015).
  CASGoogle Scholar
• 52 Petit JM, Benichou M, Duvillard L et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am. J. Gastroenterol. 98(5), 1150–1154 (2003).
  Medline CASGoogle Scholar
• 53 Khattab MA, Eslam M, Aly MM et al. Serum lipids and chronic hepatitis C genotype 4: interaction and significance. Ann. Hepatol. 11(1), 37–46 (2012).
  Medline CASGoogle Scholar
• 54 Beinhardt S, Aberle JH, Strasser M et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 142(1), 78–85.e2 (2012).
  Medline CASGoogle Scholar